Interestingly, nanoparticles containing curcumin and catalase with poly(lactic-co-glycolic acid)-based surface functionalized with pluronic F127 enhanced mucus penetration and ROS-responsive drug release capacities for the delivery of curcumin to colitis tissues, thus resulting in more effective IBD therapy [71]. The gene discussed is CAT; the disease is inflammatory bowel disease.